Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution

    Medicine, Volume 95, Issue 31, 2016.

    Cited by: 0|Bibtex|Views3|Links
    WOS

    Abstract:

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as standard therapies for advanced nonsmall cell lung cancer (NSCLC) patients with EGFR mutation positive. Because these targeted therapies could cause tumor necrosis and shrinkage, the purpose of the study is to search for a value of optimal tumor shrinkag...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments